A double-blind, randomized, multicenter, Italian study of frovatriptan versus rizatriptan for the acute treatment of migraine

Table 3 Result of consistency analysis for the secondary study endpoints

	ITT (n = 125)		p
	Frovatriptan	Rizatriptan	p
Pain-free episodes at 2 h	88 (75)	108 (77)	NS
Recurrent episodes (IHS)	13 (52)	31 (51)	NS
Recurrent episodes (protocol)	49 (64)	85 (73)	NS
Sustained pain-free episodes	61 (66)	57 (71)	NS
Pain relief episodes at 2 h	132 (85)	127 (77)	<0.05

Consistency of response was defined as responders in 2 and 3 out of 3 attacks. Data are shown for the intention-to-treat population and reported as absolute (n) and relative (%) frequency. p refer to the statistical significance of the difference between the two treatment groups

ISSN: 1129-2377